Augmented IL-15Rα Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice

被引:44
作者
Zhang, Meili [1 ,2 ]
Ju, Wei [1 ]
Yao, Zhengsheng [1 ]
Yu, Ping [1 ]
Wei, Bih-Rong [2 ,3 ]
Simpson, R. Mark [3 ]
Waitz, Rebecca [4 ]
Fasso, Marcella [5 ]
Allison, James P. [4 ]
Waldmann, Thomas A. [1 ]
机构
[1] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] NCI, Lab Anim Sci Program, Sci Applicat Int Corp Frederick Inc, Frederick, MD 21702 USA
[3] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[4] Mem Sloan Kettering Canc Ctr, Ludwig Ctr Canc Immunotherapy, Howard Hughes Med Inst, New York, NY 10065 USA
[5] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA
基金
美国国家卫生研究院;
关键词
DENDRITIC CELLS; NATURAL-KILLER; POTENTIAL ROLE; GROWTH-FACTOR; BETA-CHAIN; IN-VIVO; INTERLEUKIN-15; NK; THERAPY; PROLIFERATION;
D O I
10.4049/jimmunol.1102604
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IL-15 has potential as an immunotherapeutic agent for cancer treatment because it is a critical factor for the proliferation and activation of NK and CD8(+) T cells. However, monotherapy of patients with malignancy with IL-15 that has been initiated may not be optimal, because of the limited expression of the private receptor, IL-15R alpha. We demonstrated greater CD8 T cell-mediated therapeutic efficacy using a combination regimen of murine IL-15 administered with an agonistic anti-CD40 Ab (FGK4.5) that led to increased IL-15R alpha expression on dendritic cells (DCs), as well as other cell types, in a syngeneic established TRAMP-C2 tumor model. Seventy to one hundred percent of TRAMP-C2 tumor-bearing wild-type C57BL/6 mice in the combination group manifested sustained remissions, whereas only 0-30% in the anti-CD40-alone group and none in the murine IL-15-alone group became tumor free (p < 0.001). However, the combination regimen showed less efficacy in TRAMP-C2 tumor-bearing IL-15R alpha(-/-) mice than in wild-type mice. The combination regimen significantly increased the numbers of TRAMP-C2 tumor-specific SPAS-1/SNC9-H-8 tetramer(+)CD8(+) T cells, which were associated with the protection from tumor development on rechallenge with TRAMP-C2 tumor cells. Using an in vitro cytolytic assay that involved NK cells primed by wild-type or IL-15R alpha(-/-) bone marrow-derived DCs, we demonstrated that the expression of IL-15R alpha by DCs appeared to be required for optimal IL-15-induced NK priming and killing. These findings support the view that anti-CD40-mediated augmented IL-15R alpha expression was critical in IL-15-associated sustained remissions observed in TRAMP-C2 tumor-bearing mice receiving combination therapy. The Journal of Immunology, 2012, 188: 6156-6164.
引用
收藏
页码:6156 / 6164
页数:9
相关论文
共 39 条
[1]   THE INTERLEUKIN (IL)-2 RECEPTOR-BETA CHAIN IS SHARED BY IL-2 AND A CYTOKINE, PROVISIONALLY DESIGNATED IL-T, THAT STIMULATES T-CELL PROLIFERATION AND THE INDUCTION OF LYMPHOKINE-ACTIVATED KILLER-CELLS [J].
BAMFORD, RN ;
GRANT, AJ ;
BURTON, JD ;
PETERS, C ;
KURYS, G ;
GOLDMAN, CK ;
BRENNAN, J ;
ROESSLER, E ;
WALDMANN, TA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (11) :4940-4944
[2]   Potential role for interleukin-15 in the regulation of human natural killer cell survival [J].
Carson, WE ;
Fehniger, TA ;
Haldar, S ;
Eckhert, K ;
Lindemann, MJ ;
Lai, CF ;
Croce, CM ;
Baumann, H ;
Caligiuri, MA .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (05) :937-943
[3]   IL-15:: targeting CD8+ T cells for immunotherapy [J].
Diab, A ;
Cohen, AD ;
Alpdogan, O ;
Perales, MA .
CYTOTHERAPY, 2005, 7 (01) :23-35
[4]   IL-15Rα recycles and presents IL-15 in trans to neighboring cells [J].
Dubois, S ;
Mariner, J ;
Waldmann, TA ;
Tagaya, Y .
IMMUNITY, 2002, 17 (05) :537-547
[5]   Preassociation of IL-15 with IL-15Rα-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action [J].
Dubois, Sigrid ;
Patel, Hiral J. ;
Zhang, Meili ;
Waldmann, Thomas A. ;
Mueller, Juergen R. .
JOURNAL OF IMMUNOLOGY, 2008, 180 (04) :2099-2106
[6]   Survival adjustment of mature dendritic cells by IL-15 [J].
Dubois, SP ;
Waldmann, TA ;
Müller, JR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (24) :8662-8667
[7]   IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: The potential role of NK cell subpopulations [J].
Evans, R ;
Fuller, JA ;
Christianson, G ;
Krupke, DM ;
Troutt, AB .
CELLULAR IMMUNOLOGY, 1997, 179 (01) :66-73
[8]   SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade [J].
Fasso, Marcella ;
Waitz, Rebecca ;
Hou, Yafei ;
Rim, Tae ;
Greenberg, Norman M. ;
Shastri, Nilabh ;
Fong, Lawrence ;
Allison, James P. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (09) :3509-3514
[9]   Interleukin-2 and interleukin-15: immunotherapy for cancer [J].
Fehniger, TA ;
Cooper, MA ;
Caligiuri, MA .
CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (02) :169-183
[10]   Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation [J].
French, Ruth R. ;
Taraban, Vadim Y. ;
Crowther, Graham R. ;
Rowley, Tania F. ;
Gray, Juliet C. ;
Johnson, Peter W. ;
Tutt, Alison L. ;
Al-Shamkhani, Aymen ;
Glennie, Martin J. .
BLOOD, 2007, 109 (11) :4810-4815